Article in Cancer gene therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
Haruki HoriguchiDepartment of Molecular Genetics, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, 860-8556, Japan. horiguti@kumamoto-u.ac.jp.ORCID 0000-0001-9344-8362
Tsuyoshi KadomatsuDepartment of Molecular Genetics, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, 860-8556, Japan.ORCID 0000-0003-3327-6954
Tomoya YamashitaDepartment of Molecular Genetics, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, 860-8556, Japan.
Shinsei YumotoDepartment of Molecular Genetics, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, 860-8556, Japan.
Taichi HorinoDepartment of Molecular Genetics, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, 860-8556, Japan.ORCID 0000-0003-1355-6772
Michio SatoDepartment of Molecular Genetics, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, 860-8556, Japan.
Kazutoyo TeradaDepartment of Molecular Genetics, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, 860-8556, Japan.
Keishi MiyataDepartment of Molecular Genetics, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, 860-8556, Japan.ORCID 0000-0003-0336-1859
Yuki IchigozakiDepartment of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, 860-8556, Japan.
Toshihiro KimuraDepartment of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, 860-8556, Japan.
Satoshi FukushimaDepartment of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, 860-8556, Japan.ORCID 0000-0002-0622-7682
Toshiro MoroishiCenter for Metabolic Regulation of Healthy Aging (CMHA), Graduate School of Medical Sciences, Kumamoto University, Kumamoto, 860-8556, Japan.ORCID 0000-0001-6419-3882
Yuichi OikeDepartment of Molecular Genetics, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, 860-8556, Japan. oike@gpo.kumamoto-u.ac.jp.ORCID 0000-0003-3245-5395
Funding
Ministry of Education, Culture, Sports, Science and Technology (MEXT) 21K07101Ministry of Education, Culture, Sports, Science and Technology (MEXT) 23K06638
6 · The paper itself
Abstract
Use of immune checkpoint inhibitors (ICIs) as cancer immunotherapy has advanced rapidly in the clinic. We recently reported that tumor stroma-derived angiopoietin-like protein 2 (ANGPTL2) has tumor suppressive activity by enhancing dendritic cell-mediated CD8
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Tumor stroma-derived ANGPTL2 potentiates immune checkpoint inhibitor efficacy. · full record | OpenQuestion